The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...
1don MSN
US FDA approves first AI tool for liver disease trials: How AIM-NASH transforms biopsy reading
NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologists ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...
PathAI, a leading provider of AI-powered pathology, will give a late-breaker presentation on new results from analytical and clinical validation studies that tested their AIM-NASHTM product and ...
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...
VIENNA – Treatment with an investigational FGF21 analogue improved fibrosis in patients with nonalcoholic steatohepatitis (NASH), according to a phase IIb trial. In the ENLIVEN study, patients with ...
May 4, 2010 — Supplementation with the natural form of vitamin E (800 IU/day) has beneficial effects in patients with nonalcoholic steatohepatitis (NASH), but pioglitazone's benefits are less clear, ...
For patients with nonalcoholic fatty liver disease (NAFLD) who supplement their diets with polyunsaturated fatty acids (PUFA), liver and metabolic parameters improve, results of a systematic review ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback